Skip to main content
SpringerLink
Log in

Transfusion Support of the Patient with Hematologic Malignancy

  • Chapter
  • First Online:
Leukemia and Related Disorders

Part of the book series: Contemporary Hematology ((CH))

  • 1598 Accesses

Abstract

Recent advances have markedly improved survival outcomes in the treatment of leukemia and other hematologic malignancies, but despite new techniques in growth factor and stem cell technology, chronic or prolonged periods of pancytopenia remain a significant problem, and transfusion is a cornerstone of management. An evidence-based approach to best practice must take into account indications for transfusions as well as their risks.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Slichter SJ, Kaufman RM, Assman SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362:600–13.

    Article  PubMed  CAS  Google Scholar 

  2. Heddle NM, Cook RJ, Sigouin C, et al. A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia. Transfusion. 2006;46:903–11.

    Article  PubMed  Google Scholar 

  3. George T, Ho-Tin-Noe B, Carbo C, et al. Inflammation induces hemorrhage in thrombocytopenia. Blood. 2008;111:4958–64.

    Article  CAS  Google Scholar 

  4. Bernstein S, Nademanee A, et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood. 1998;9:3509–17.

    Google Scholar 

  5. Kitchens CS, Weiss L. Ultrastructural changes of endothelium associated with thrombocytopenia. Blood. 1975;46:567–78.

    PubMed  CAS  Google Scholar 

  6. Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med. 1962;266:905–9.

    Article  PubMed  CAS  Google Scholar 

  7. Han T, Stutzman L, Cohen E. Effect of platelet transfusion on hemorrhage in patients with acute leukemia. Cancer. 1966;1919:37–42.

    Google Scholar 

  8. Harker LA, Slichter SJ. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med. 1972;287:155–9.

    Article  PubMed  CAS  Google Scholar 

  9. Blajchman MA, Slichter SJ, Heddle NM, Murphy MF. New strategies for the optimal use of platelet transfusions. Hematology Am Soc Hematol Educ Program 2008;198–204.

    Google Scholar 

  10. Slichter SJ, LeBlanc R, Jones MK, et al. Quantitative analysis of bleeding risk in cancer patients prophylactically transfused at platelet counts of 5,000, 10,000, or 20,000 platelets/μl. Blood. 1999;94:376a.

    Google Scholar 

  11. Heckman KD, et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/uL Vs 20,000/uL. J Clin Oncol. 1997;15:1143–9.

    PubMed  CAS  Google Scholar 

  12. Wandt H, et al. Safety and cost effectiveness of a 10 X 109/L trigger for prophylactic platelet transfusions compared to the traditional 20 X 109/L: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91:3601–6.

    PubMed  CAS  Google Scholar 

  13. Gmur J, et al. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukemia. Lancet. 1991;338:1223–6.

    Article  PubMed  CAS  Google Scholar 

  14. Rebulla P, Finazzi G, Marangoni R, et al. A multicenter randomized trial of the threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med. 1997;337:1870–5.

    Article  PubMed  CAS  Google Scholar 

  15. Wandt H, Schaefer-Eckart K, Frank M, et al. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006;37:387–92.

    Article  PubMed  CAS  Google Scholar 

  16. Pisciotto PT, Benson K, Hume H, et al. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion. 1995;35:498–502.

    Article  PubMed  CAS  Google Scholar 

  17. Miller AB, Hoogstraten B, Staquat M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–14.

    Article  PubMed  CAS  Google Scholar 

  18. Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood. 1985;66:1105–9.

    PubMed  CAS  Google Scholar 

  19. George T, Ho-Tin-Noe B, Carbo C, et al. Inflammation induces hemorrhage in thrombocytopenia. Blood. 2008;111:4958–64.

    Article  CAS  Google Scholar 

  20. Klumpp TR, Herman JH, Gaughan JP, et al. Clinical consequences of alterations I platelet transfusion dose: a prospective, randomized, double-blinded trial. Transfusion. 1999;39:674–81.

    Article  PubMed  CAS  Google Scholar 

  21. Norol F, Bierling P, Roudot-Thoraval F, et al. Platelet transfusion: a dose–response study. Blood. 1998;92:1448–53.

    PubMed  CAS  Google Scholar 

  22. Sensebé L, Giraudeau B, Bardiau L, et al. The efficiency of transfusion high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. Blood. 2005;105:862–4.

    Article  PubMed  CAS  Google Scholar 

  23. Heddle NM, Cook RJ, Tinmouth A, et al. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood. 2009;113:1564–73.

    Article  PubMed  CAS  Google Scholar 

  24. Welsh KI, Burgos H, Batchelor JR. The immune response to allogeneic rat platelets: Ag-B antigens in matrix lacking Ia. Eur J Immunol. 1977;7:267–72.

    Article  PubMed  CAS  Google Scholar 

  25. Batchelor JR, Welsh KI, Burgos H. Transplantation antigens per se are poor immunogens within a species. Nature. 1978;273:54–6.

    Article  PubMed  CAS  Google Scholar 

  26. Claas FHJ, Smeenk RJT, Schmidt R, et al. Alloimmunization against the MHC antigens after platelet transfusion is due to contaminating leukocytes in the platelet suspension. Exp Hematol. 1981;9:84–9.

    PubMed  CAS  Google Scholar 

  27. Sniecinski I, O’Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood. 1988;5:1402–7.

    Google Scholar 

  28. Schiffer CA, Dutcher JP, Aisner J, Hogge D, Wiernik PH, Reilly JP. A randomized trial of leukocyte depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood. 1983;62:815–20.

    PubMed  CAS  Google Scholar 

  29. Murphy MF, Metcalfe P, Thomas H, et al. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol. 1986;62:529–34.

    Article  PubMed  CAS  Google Scholar 

  30. Trial to Reduce Alloimmunization to Platelets (TRAP) Trial Study Group. A randomized trial evaluating leukocyte-reduction and UV-B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337:1861–9.

    Article  Google Scholar 

  31. Slichter SJ. Principles of platelet transfusion therapy. In: Hoffman R, Benz Jr EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, editors. Hematology: basic principles and practice. 2nd ed. New York: Churchill Livingstone; 1995. p. 1987–2006.

    Google Scholar 

  32. Toor A, Choo S, et al. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation. Bone Marrow Transplant. 2000;26:315–20.

    Article  PubMed  CAS  Google Scholar 

  33. Ishida A, Handa M, et al. Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation – a prospective analysis. Transfusion. 1998;38:839–47.

    Article  PubMed  CAS  Google Scholar 

  34. Bishop J, McGrath K, et al. Clinical factors influencing efficacy of pooled platelet transfusions. Blood. 1988;71:383–7.

    PubMed  CAS  Google Scholar 

  35. Alcorta I, Pereira A, et al. Clinical and laboratory factors associated with platelet transfusion refractoriness: a case–control study. Br J Haem. 1996;93:220–4.

    Article  CAS  Google Scholar 

  36. Gmur J, von Felten A, et al. Delayed alloimmunization using random single donor platelet transfusions: a prospective study in thrombocytopenic patients with acute leukemia. Blood. 1983;62:473–9.

    PubMed  CAS  Google Scholar 

  37. Sintnicolaas K, Vriesendorp H, et al. Delayed alloimmunization by random single donor platelet transfusions. Lancet. 1981;317:750–4.

    Article  Google Scholar 

  38. Kakaiya RM, Hezzey AJ, Bove JR, et al. Alloimmunization following apheresis platelets vs. pooled platelet concentrate transfusion-a prospective randomized study. Transfusion. 1981;21:600a.

    Google Scholar 

  39. Delaflor-Weiss E, Mintz PD. The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev. 2000;14:180–96.

    Article  PubMed  CAS  Google Scholar 

  40. Pai S-C, Lo S-C, Lin Tsai S-J, et al. Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases. Transfusion. 2010;50:2318–27.

    Article  PubMed  CAS  Google Scholar 

  41. Friedberg RC, Donnelly SF, Mintz PD. Independent roles for platelet crossmatching and HLA in the selection of platelets for alloimmunized patients. Transfusion. 1994;34:215–20.

    Article  PubMed  CAS  Google Scholar 

  42. Bierling P, Cordonnier C, Rodet M, et al. High dose intravenous gammaglobulin and platelet transfusions in leukaemic HLA-immunized patients. Scand J Haematol. 1984;33:215–20.

    Article  PubMed  CAS  Google Scholar 

  43. Kickler T, Braine HG, Piantadosi S, et al. A randomized placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. Blood. 1990;75:313–6.

    PubMed  CAS  Google Scholar 

  44. Lee EJ, Norris D, Schiffer CA. Intravenous immune globulin for patients alloimmunized to random donor platelet transfusion. Transfusion. 1987;27:245–7.

    Article  PubMed  CAS  Google Scholar 

  45. Carr R, Hutton J, et al. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. Br J Haem. 1990;75:408–13.

    Article  CAS  Google Scholar 

  46. Cattaneo M, Mannucci PM. Current status of non-transfusional haemostatic agents. Haematologica. 1999;84(Suppl EHA-4):120–3.

    PubMed  Google Scholar 

  47. Valeri CR, Cassidy G, Pivacek LE, et al. Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion. 2001;41:977–83.

    Article  PubMed  CAS  Google Scholar 

  48. Bartholomew JR, Salgia R, Bell WR. Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid. Arch Intern Med. 1989;149:1959–61.

    Article  PubMed  CAS  Google Scholar 

  49. Garewal HS, Durie BGM. Antifibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. Scand J Haematol. 1985;35:497–500.

    Article  PubMed  CAS  Google Scholar 

  50. Mannucci PM. Desmopressin: a nontransfusional hemostatic agent. Annu Rev Med. 1990;41:55–64.

    Article  PubMed  CAS  Google Scholar 

  51. Poon MC. The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders. Transfus Med Rev. 2007;21:223–36.

    Article  PubMed  Google Scholar 

  52. Norol F, Kuentz M, et al. Influence of clinical status on the efficiency of stored platelet transfusion. Br J Haem. 1994;86:125–9.

    Article  CAS  Google Scholar 

  53. Kantarjian HM, Giles FJ, Greenberg PL, et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010;116:3163–70.

    Article  PubMed  CAS  Google Scholar 

  54. Birgegard G, Gascon P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol. 2006;77(5):378–86.

    Article  PubMed  Google Scholar 

  55. Spivak JL, Gascon P, Ludwig H. Anemia management in oncology and hematology. Oncologist. 2009;14 Suppl 1:43–56.

    Article  PubMed  CAS  Google Scholar 

  56. Coiffier B, Guastalla JP, Pujade-Lauraine E, Bastit P, Anemia Study Group. Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: Results of a retrospective survey. Eur J Cancer. 2001;37(13):1617–23.

    Article  PubMed  CAS  Google Scholar 

  57. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, Lofvenberg E, Oberg G, Porwit-MacDonald A, Radlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F, Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120(6):1037–46.

    Article  PubMed  CAS  Google Scholar 

  58. Moullet I, Salles G, Ketterer N, Dumontet C, Bouafia F, Neidhart-Berard EM, Thieblemont C, Felman P, Coiffier B. Frequency and significance of anemia in non Hodgkin’s lymphoma patients. Ann Oncol. 1998;9(10):1109–15.

    Article  PubMed  CAS  Google Scholar 

  59. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion requirements in critical care investigators, Canadian critical care trials group. N Engl J Med. 1999;340(6):409–17.

    Article  PubMed  CAS  Google Scholar 

  60. Blajchman MA, Bordin JO, Bardossy L, Heddle NM. The contribution of the haematocrit to thrombocytopenic bleeding in experimental animals. Br J Haematol. 1994;86(2):347–50.

    Article  PubMed  CAS  Google Scholar 

  61. Hendrickson JE, Desmarets M, Deshpande SS, Chadwick TE, Hillyer CD, Roback JD, Zimring JC. Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells. Transfusion. 2006;46(9):1526–36.

    Article  PubMed  CAS  Google Scholar 

  62. Seyfried H, Walewska I. Analysis of immune response to red blood cell antigens in multitransfused patients with different diseases. Mater Med Pol. 1990;22(1):21–5.

    PubMed  CAS  Google Scholar 

  63. Arriaga F, Bonanad S, Larrea L, de la Rubia J, Lopez F, Sanz MA, Sanz G, Marty ML. Immunohematologic study in 112 patients with myelodysplastic syndromes: 10-year analysis. Sangre (Barc). 1995;40(3):177–80.

    CAS  Google Scholar 

  64. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993;328:1323–32.

    Article  PubMed  CAS  Google Scholar 

  65. Engels EA, Ellis CA, Supran SE, et al. Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk. Clin Infect Dis. 1999;28:256–66.

    Article  PubMed  CAS  Google Scholar 

  66. McCullough J, Weiblen B, et al. In vitro function and post-transfusion survival of granulocytes collected by continuous-flow centrifugation and by filtration leukapheresis. Blood. 1976;2:315–26.

    Google Scholar 

  67. Dutcher J, Schiffer C, Johnston G. Rapid migration of indium-labeled granulocytes to sites of infection. N Engl J Med. 1981;304:586–9.

    Article  PubMed  CAS  Google Scholar 

  68. Lowenthal RM, Grossman L, Goldman JM, et al. Granulocyte transfusions in treatment of infections in patients with acute leukemia and aplastic anemia. Lancet. 1975;1(7903):353–8.

    Article  PubMed  CAS  Google Scholar 

  69. Alavi J, Root R, et al. A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med. 1977;13:706–11.

    Article  Google Scholar 

  70. Vogler W, Winton E. A controlled study of the efficacy of granulocyte transfusions in patients with neutropenia. Am J Med. 1977;4:548–55.

    Article  Google Scholar 

  71. Clift RA, Sanders JE, Thomas ED, et al. Granulocyte transfusions for the prevention of infection in patients receiving bone marrow transplants. N Engl J Med. 1978;298:1052–7.

    Article  PubMed  CAS  Google Scholar 

  72. Adkins D, Goodnough L, et al. Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation. Blood. 2000;11:3605–12.

    Google Scholar 

  73. Schiffer C, Aisner J, et al. Alloimmunization following prophylactic granulocyte transfusion. Blood. 1979;54:766–74.

    PubMed  CAS  Google Scholar 

  74. Caspar CB, Seger RA, Burger J, Gmur J. Effective stimulation of donors for granulocyte transfusion with recombinant methionyl granulocyte colony-stimulating factor. Blood. 1993;81:2866–71.

    PubMed  CAS  Google Scholar 

  75. Price TH, Bowden RA, Boeckh M, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood. 2000;95:3302–9.

    PubMed  CAS  Google Scholar 

  76. Dzik WH. The NHLBI clinical trials network in transfusion medicine and hemostasis: an overview. J Clin Apheresis. 2006;21:57–9.

    Article  PubMed  Google Scholar 

  77. Savage WJ, Tobian AA, Fuller AK, Wood RA, King KE, Ness PM. Allergic transfusion reactions to platelets are associated more with recipient and donor factors than with product attributes. Transfusion. 2011;51(8):1716–22. Epub 2011 Jan 7.

    Article  PubMed  Google Scholar 

  78. Tobian AA, Savage WJ, Tisch DJ, Thoman S, King KE, Ness PM. Prevention of allergic transfusion reactions to platelets and red blood cells through plasma reduction. Transfusion. 2011;51(8):1716–22. Epub 2011 Jan 7.

    Article  PubMed  Google Scholar 

  79. Heddle NM, Klama L, Singer J, Richards C, Fedak P, Walker I, Kelton JG. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med. 1994;331(10):625–8.

    Article  PubMed  CAS  Google Scholar 

  80. Wang SE, Lara Jr PN, Lee-Ow A, Reed J, Wang LR, Palmer P, Tuscano JM, Richman CM, Beckett L, Wun T. Acetaminophen and diphenhydramine as premedication for platelet transfusions: A prospective randomized double-blind placebo-controlled trial. Am J Hematol. 2002;70(3):191–4.

    Article  PubMed  CAS  Google Scholar 

  81. Geiger TL, Howard SC. Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice? Transfus Med Rev. 2007;21(1):1–12.

    Article  PubMed  Google Scholar 

  82. Patterson BJ, Freedman J, Blanchette V, Sher G, Pinkerton P, Hannach B, Meharchand J, Lau W, Boyce N, Pinchefsky E, Tasev T, Pinchefsky J, Poon S, Shulman L, MacK P, Thomas K, Blanchette N, Greenspan D, Panzarella T. Effect of premedication guidelines and leukoreduction on the rate of febrile nonhaemolytic platelet transfusion reactions. Transfus Med. 2000;10(3):199–206.

    Article  PubMed  CAS  Google Scholar 

  83. Couban S, Carruthers J, Andreou P, Klama LN, Barr R, Kelton JG, Heddle NM. Platelet transfusions in children: results of a randomized, prospective, crossover trial of plasma removal and a prospective audit of WBC reduction. Transfusion. 2002;42(6):753–8.

    Article  PubMed  Google Scholar 

  84. Ahrens N, Pruss A, Kiesewetter H, Salama A. Failure of bedside ABO testing is still the most common cause of incorrect blood transfusion in the barcode era. Transfus Apher Sci. 2005;33(1):25–9.

    Article  PubMed  Google Scholar 

  85. Janatpour KA, Kalmin ND, Jensen HM, Holland PV. Clinical outcomes of ABO incompatible RBC transfusions. Am J Clin Pathol. 2008;129(2):276–81.

    Article  PubMed  Google Scholar 

  86. Wagner SJ. Transfusion-transmitted bacterial infection: risks, sources and interventions. Vox Sang. 2004;86(3):157–63.

    Article  PubMed  CAS  Google Scholar 

  87. Holness L, Knippen MA, Simmons L, Lachenbruch PA. Fatalities caused by TRALI. Transfus Med Rev. 2004;18(3):184–8.

    Article  PubMed  Google Scholar 

  88. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion related acute lung injury. Transfusion. 1985;25(6):573–7.

    Article  PubMed  CAS  Google Scholar 

  89. Silliman CC, Paterson AJ, Dickey WO, Stroneck DF, Popovsky MA, Caldwell SA, Ambruso DR. The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study. Transfusion. 1997;37(7):719–26.

    Article  PubMed  CAS  Google Scholar 

  90. Kleinman S, Caulfield T, Chan P, Davenport R, McFarland J, McPhedran S, Meade M, Morrison D, Pinsent T, Robillard P, Slinger P. Toward an understanding of transfusion related acute lung injury: statement of a consensus panel. Transfusion. 2004;44(12):1774–89.

    Article  PubMed  Google Scholar 

  91. Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood. 2005;105(6):2266–73.

    Article  PubMed  CAS  Google Scholar 

  92. Rana R, Fernandez-Perez ER, Khan SA, Rana S, Winters JL, Lesnick TG, Moore SB, Gajic O. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion. 2006;46(9):1478–83.

    Article  PubMed  Google Scholar 

  93. Jeddi R, Mansouri R, Kacem K, Gouider E, Abid HB, Belhadjali Z, Meddeb B. Transfusion-related acute lung injury (TRALI) during remission induction course of acute myeloid leukemia: a possible role for all-transretinoic-acid (ATRA)? Pathol Biol (Paris). 2009;57(6):500–2.

    Article  CAS  Google Scholar 

  94. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med. 1990;323:315–21.

    Article  PubMed  CAS  Google Scholar 

  95. Greenbaum BH. Transfusion-associated graft-versus-host disease: historical perspectives, incidence, and current Use of irradiated blood products. J Clin Oncol. 1991;9:1889–902.

    PubMed  CAS  Google Scholar 

  96. Sprent J, Anderson RE, Miller JFAP. Radiosensitivity of T and B lymphocytes. II. Effect of irradiation on response of T cells to alloantigens. Eur J Immunol. 1974;4:204–10.

    Article  PubMed  CAS  Google Scholar 

  97. BCSH Blood Transfusion Task Force. Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. Transfus Med. 1996;6:261–71.

    Article  Google Scholar 

  98. Lin L, Dikeman R, Molini B, et al. Photochemical treatment of platelet concentrates with amotosalen and UVA inactivates a broad spectrum of pathogenic bacteria. Transfusion. 2004;44:1496–504.

    Article  PubMed  CAS  Google Scholar 

  99. Grass JA, Wafa T, Reames A, et al. Prevention of transfusion associated graft-versus-host disease by photochemical treatment. Blood. 1999;93:3140–7.

    PubMed  CAS  Google Scholar 

  100. Akahoshi M, Takanashi M, Masuda M, et al. A case of transfusion-associated graft-versus-host disease not prevented by white cell-reduction filters. Transfusion. 1992;32:169–72.

    Article  PubMed  CAS  Google Scholar 

  101. Clair P, Embil J, Fahey J. A seroepidemiologic study of cytomegalovirus infection in a Canadian recruit population. Mil Med. 1990;155:489–92.

    PubMed  CAS  Google Scholar 

  102. Tegtmeier GE. Post transfusion cytomegalovirus infections. Arch Pathol Lab Med. 1989;113:236–45.

    PubMed  CAS  Google Scholar 

  103. Meyers J, Flournoy N, et al. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986;153:478–88.

    Article  PubMed  CAS  Google Scholar 

  104. Konoplev S, Champlin RE, et al. Cytomegalovirus pneumonia in adult autologous blood marrow transplant recipients. Bone Marrow Transplant. 2001;27:877–81.

    Article  PubMed  CAS  Google Scholar 

  105. Enright H, Haake R, et al. Cytomegalovirus pneumonia after bone marrow transplantation. Transplantation. 1993;55:1339–45.

    Article  PubMed  CAS  Google Scholar 

  106. Reusser P. The challenge of cytomegalovirus infection after bone marrow transplantation: epidemiology, prophylaxis and therapy. Bone Marrow Transplant. 1996;18:107–9.

    PubMed  Google Scholar 

  107. Goodrich J, Bowden R, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173–8.

    PubMed  CAS  Google Scholar 

  108. Winston D, Ho W, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med. 1993;118:179–84.

    PubMed  CAS  Google Scholar 

  109. Bowden R, Slichter S, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995;86:3598–603.

    PubMed  CAS  Google Scholar 

  110. DeWitte T, Schattenberg A, et al. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood bank donors. Transplantation. 1990;50:964–8.

    Article  CAS  Google Scholar 

  111. de Graan-Hentzen Y, Gratama J, et al. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion. 1989;29:757–60.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA

    Terry B. Gernsheimer M.D.

  2. Transfusion Services, Seattle Cancer Care Alliance, Seattle, WA, USA

    Terry B. Gernsheimer M.D.

  3. Puget Sound Blood Center, 921 Terry Avenue, 98104, Seattle, WA, USA

    Terry B. Gernsheimer M.D.

  4. Department of Laboratory Medicine, Puget Sound Blood Center, 921 Terry Avenue, 98104, Seattle, WA, USA

    Meghan Delaney DO, PMH (Assistant Medical Director)

Authors
  1. Terry B. Gernsheimer M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meghan Delaney DO, PMH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Terry B. Gernsheimer M.D. .

Editor information

Editors and Affiliations

  1. Univ of Washington School of Medicine, Member,, Professor of Med, Division of Hematology, Attending Physician, Seattle Cancer Care Alliance, Seattle, 98109-1024, Washington, USA

    Elihu H. Estey

  2. Director, Clinical Research Division,, Fred Hutchinson Cancer Research Center, Professor of Medicine; Head of Oncology, Seattle Cancer Care Alliance, Univ of Washington Sch of Med, Seattle, 98109-1024, Washington, USA

    Fred R. Appelbaum

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Gernsheimer, T.B., Delaney, M. (2012). Transfusion Support of the Patient with Hematologic Malignancy. In: Estey, E., Appelbaum, F. (eds) Leukemia and Related Disorders. Contemporary Hematology. Springer, New York, NY. https://doi.org/10.1007/978-1-60761-565-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-565-1_11

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-60761-564-4

  • Online ISBN: 978-1-60761-565-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation